Nano Cap New Millennium Growth Fund L P Acquires Shares of 80,000 BioAge Labs, Inc. $BIOA

Nano Cap New Millennium Growth Fund L P acquired a new stake in BioAge Labs, Inc. (NASDAQ:BIOA) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 80,000 shares of the company’s stock, valued at approximately $1,058,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Strs Ohio grew its stake in shares of BioAge Labs by 26.4% during the fourth quarter. Strs Ohio now owns 22,500 shares of the company’s stock valued at $298,000 after acquiring an additional 4,700 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of BioAge Labs during the fourth quarter valued at about $77,000. CWM LLC grew its stake in shares of BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after acquiring an additional 1,053 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after acquiring an additional 10,000 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of BioAge Labs by 228.7% during the third quarter. JPMorgan Chase & Co. now owns 36,848 shares of the company’s stock valued at $217,000 after acquiring an additional 25,638 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BIOA. Citigroup raised their target price on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Piper Sandler began coverage on BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Needham & Company LLC started coverage on BioAge Labs in a research note on Friday, March 27th. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. Finally, BTIG Research started coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

BioAge Labs Stock Up 3.9%

Shares of BIOA stock opened at $16.74 on Friday. The business has a 50 day moving average of $17.82 and a two-hundred day moving average of $16.11. BioAge Labs, Inc. has a 52 week low of $3.79 and a 52 week high of $24.00. The company has a market cap of $744.09 million, a P/E ratio of -6.97 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Analysts expect that BioAge Labs, Inc. will post -2.59 EPS for the current fiscal year.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.